
Patients with pancreatic cancer normally present with advanced disease that is lethal and notoriously difficult to zzso Survival has not improved dramatically despite routine use of chemotherapy and zzso this situation zzso an urgent need for novel therapeutic zzso Over the past decade, a large number of studies have been published that aimed to target the molecular abnormalities implicated in pancreatic tumor growth, invasion, zzso zzso and resistance to zzso This research is of particular importance, as data suggest that a large number of genetic zzso affect only a few major signaling pathways and processes involved in pancreatic zzso Although laboratory results of targeted therapies have been impressive, until now only zzso an zzso growth factor zzso zzso zzso zzso has demonstrated modest survival benefit in combination with zzso in a phase III clinical zzso zzso the failures of targeted therapies in the clinical setting are zzso lessons have been zzso and new therapeutic targets that hold promise for the future management of the disease are continuously zzso This Review describes some of the important developments and targeted agents for pancreatic cancer that have been tested in clinical zzso 

